Table 1.
Patient characteristics.
| Factors | Items | Value | Unit | |
|---|---|---|---|---|
| Age | Median | 65 | years | |
| Range | 39–86 | years | ||
| Performance status (ECOG) | 0 | 200 | (98%) | |
| 1 | 4 | (2%) | ||
| Follow-up time | Median | 52 | months | |
| Range | 24–76 | months | ||
| Initial PSA (ng/ml) | <10 | 140 | (69%) | |
| 10–20 | 44 | (22%) | ||
| ≥20 | 20 | (10%) | ||
| Gleason score | 6 | 18 | (9%) | |
| 7 | 125 | (61%) | ||
| 8 | 41 | (20%) | ||
| ≥9 | 20 | (10%) | ||
| Clinical T stage (UICC) | T1c | 88 | (43%) | |
| T2a | 70 | (34%) | ||
| T2b | 11 | (5%) | ||
| T2c | 18 | (9%) | ||
| T3a | 14 | (7%) | ||
| T3b | 3 | (1%) | ||
| Risk stratification | Intermediate | 112 | (55%) | |
| High | 92 | (45%) | ||
| Prescription dose (GyE) | 70 | 26 | (Intermediate, 13%) | |
| 35 | (High, 17%) | |||
| 74 | 85 | (42%) | ||
| 78 | 58 | (28%) | ||
| Anticoagulants | Yes | 30 | (15%) | |
| No | 174 | (85%) | ||
| HbA1c | <6.5 | 177 | (87%) | |
| ≥6.5 | 27 | (13%) | ||
| Percentage of positive biopsy cores | Median | 25 | % | |
| Range | 5–100 | % | ||
| Perineural invasion in biopsy specimens | Yes | 11 | (5%) | |
| No | 193 | (95%) | ||
| CTV D95 | Median | 74 | GyE | |
| Range | 69–78 | GyE | ||
| PTV D95 | Median | 59 | GyE | |
| Range | 38–67 | GyE | ||
| CTV V95 | Median | 100 | % | |
| Range | 98–100 | % | ||
| PTV V95 | Median | 79 | % | |
| Range | 63–88 | % | ||
| GU toxicity (grade 2) | Late | Median | 34 | months |
| Range | 7–46 | months | ||
| Acute/Late | Retention | 30/3 | (15%/1%) | |
| Frequency | 21/1 | (10%/<1%) | ||
| Pain | 10/0 | (5%/0%) | ||
| Events | Urgency | 4/0 | (2%/0%) | |
| Hematuria | 0/4 | (0%/2%) | ||
| Incontinence | 0/1 | (0%/<1%) | ||
| GI toxicity (grade 2) | Late | Median | 12 | months |
| Range | 6–24 | months | ||
| Events | Acute/Late | Hemorrhage | 0/8 | (0%/4%) |
| PSA nadir (Value) | 70(GyE) | Median | 0.5 | ng/ml |